Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60

Moomoo News00:31 ET · Ratings

Tandem Diabetes Announces NEJM Publication Of Control-IQ+ Trial For Type 2 Diabetes, Showing Significant A1C Reductions Of 0.9% Overall And 2.3% For A1C ≥9%, Meeting Primary Endpoint

BenzingaMar 19 10:02 ET

TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $27

Moomoo NewsMar 19 02:31 ET · Ratings

Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes With Control-IQ+ AID Technology in Type 2 Diabetes

Tandem Diabetes Care Mar 19 00:00 ET

Express News | Tandem Diabetes Care Inc : TD Cowen Cuts Target Price to $27 From $40

ReutersMar 18 23:56 ET

Express News | Tandem Diabetes Care Launches New Control-Iq+ Automated Insulin Delivery Technology in the United States

ReutersMar 18 16:05 ET